<DOC>
	<DOCNO>NCT00845650</DOCNO>
	<brief_summary>The purpose study : - evaluate safety profile single intravenous administration AIGIV ( contain either 3.5 mg/kg , 7.0 mg/kg 14.0 mg/kg anti-PA IgG ) compare either 90 mg/kg , 180 mg/kg 360 mg/kg total IgG , GAMUNEX ( R ) ( immune globulin intravenous ( human ) 10 % caprylate/chromatography purify ) . GAMUNEX trademark Talecris Biotherapeutics . - evaluate pharmacokinetic ( PK ) profile single intravenous administration AIGIV ( contain either 3.5 mg/kg , 7.0 mg/kg 14.0 mg/kg anti-PA IgG ) measure lethal toxin neutralize antibody ( TNA ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study Anthrax Immune Globulin Intravenous ( AIGIV )</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Between 18 65 year age , inclusive . Have minimal weight 110 lb body mass index ( BMI ) 17 35 . In good health . For premenopausal female subject , use acceptable method birth control . Willing capable comply aspect protocol completion program period . No blood donation precede 8 week ; willing donate whole blood plasma clinical trial ; willing donate whole blood plasma one year follow last infusion . Has read sign informed consent form . Adequate venous access receive intravenous infusion . Previously intolerant immune globulin blood product preparation know immunodeficiency . Previous treatment immune globulin product blood product within three month study . Previous receipt anthrax vaccine , know exposure anthrax organism , previously enlist military . Receipt live vaccine within three month inactivate vaccine within 2 week prior study ; plan receive vaccine time study . Participation investigational clinical trial within one month prior study . Positive serology human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus . Receipt chemotherapy , radiation therapy , immunosuppressive therapy , highdose corticosteroid therapy within five year study . Use prohibit medication define protocol . History drug alcohol abuse within 1 year study . History IgA deficiency . Pregnancy . Positive Coombs test screening . Males hemoglobin value le 13.2 gm/dL female less 10.9 gm/dL . Absolute eosinophil count great 600 cells/mm3 Absolute lymphocyte count less 1000 cells/mm3 . Aspartate aminotransferase ( AST ) &gt; 55 U/L alanine aminotransferase ( ALT ) &gt; 60 U/L . Hyperglycemia random blood glucose &gt; 141 mg/dL , fast blood glucose &gt; 112 mg/dL , urine glucose &gt; 50 mg/dL ; hypoglycemia blood glucose &lt; 65 mg/dL . BUN &gt; 25 mg/dL creatinine , male &gt; 1.4 mg/dL , females &gt; 1.2 mg/dL . Urine protein &gt; 15 mg/dL male nonmenstruating female , &gt; 30 mg/dL menstruating female . Febrile illness within three day prior study . History significant medical psychiatric condition abnormal laboratory test indicate possible underlying medical condition . An opinion investigator condition exists would preclude compliance protocolspecified procedure . Absolute neutrophil count less 3000 cells/mm3 define central lab ( screen ) local lab ( preinfusion ) cohort B . Absolute neutrophil count less 2500 cells/mm3 define central lab ( screen ) local lab ( preinfusion ) cohort C. White blood cell count less 3500 cells/mm3 define central lab ( screen ) local lab ( preinfusion ) cohorts B C. History severe anaphylactic reaction quinolone penicillin antibiotic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Anthrax</keyword>
	<keyword>Human Anthrax Immune Globulin Intravenous</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>